3 Steps To Guide Your Product To Annex 1 Compliance

By Robert Keem, Vice President of Quality, August Bioservices

To fully realize the promise of biologics to transform cancer and autoimmune disorder treatment, manufacturers must appropriately reckon with their manufacturing challenges. These modalities are highly sensitive to their environmental conditions and prone to instability and degradation. Proper contamination controls, environmental monitoring, and barrier technologies are crucial to protect products en route to patients.

The EU’s GMP Annex 1 guidelines for the manufacture of sterile medicinal products provide sponsors with a comprehensive approach to protecting patient safety and product integrity throughout the lifecycle of their programs. The August 2023 update compiled years of industry best practices and regulatory feedback to establish Annex 1 as the global benchmark for contamination control; its influence is now impacting other major pharma hubs, including the U.S., China, and Japan.

To ensure continuous Annex 1 compliance, sponsors should prioritize three steps: Annex 1 literacy, partner selection, and futureproofed manufacturing. Download the full article to explore how these strategies can position therapies for both near-term regulatory success and long-term commercial viability.